Clinical Trial Update: Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature [Phase 3]

View source ↗

Summary

This update describes an amendment to the unblinded extension phase of a Phase 3 trial of somatropin in idiopathic short stature. The study status is listed as …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Short Stature

Drugs mentioned

• Somatropin (somatropin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Growth Disorder | Phase 3 | Status: COMPLETED